As a result of the COVID-19 pandemic, several neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, it seems that the omicron variant could compromise the effectiveness of the therapeutic antibodies against COVID-19 that are currently in the clinic.
A recent study available in MedRxiv (Cameroni et al. 2021), has evaluated the eight currently approved monoclonal antibodies for their in vitro neutralizing capacity against omicron variant.All, but one of these therapeutics completely lost activity against omicron. The only exception was sotrovimab. The study also tested a panel of 36 monoclonal antibodies that are not yet in the clinic, but whose epitope has been characterized structurally. Five of them (S2K146, S2X324, S2N28, S2X259 and S2H97) retained Omicron neutralization, whereas the remaining ones did not.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
